News | June 23, 2026
FDA advisory panel backs Moderna flu vaccine candidate for older adults
The backing comes as influenza remains a persistent public health burden
The backing comes as influenza remains a persistent public health burden
CEO Stéphane Bancel framed the changes as essential to scaling the business
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
NEJM study shows strong protection across strains
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
